Abstract: A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis.

Abstract: The present disclosure pertains to novel cell cultivation and cell and/or cell-derived product production processes that have advantages over currently existing fermentation strategies. The processes and methods according to the present disclosure may be used for an efficient supply of highly viable and metabolically active eukaryotic cells for transient production platforms, as an alternative production process with advantages over currently applied processes (batch, fed-batch or perfusion strategies) and for generating metabolically highly active biomass for subsequent use for transient expression systems or infection by a virus or pseudovirus or in cell-free systems.

Abstract: The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Abstract: The present invention relates to an optimized fermentation process of coenzyme Q10, particularly to a fermentation process of coenzyme Q10 via flow feeding based on cooperative control of changes of online oxygen consumption rate and conductivity. During the fermentation process of coenzyme Q10 production strains, the oxygen consumption rate is controlled between 30-150 mmol/L·h and the conductivity is maintained between 3.0-30.0 ms/cm via flow feeding, so as to facilitate strain growth and the start of coenzyme Q10 synthesis and accumulation. The present invention can substantially increase output of coenzyme Q10 and greatly reduce the production cost with simple process control and strong operability, thus being applicable to large-scale industrial production.

Abstract: The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC) hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.

Abstract: A cell patterning material, a method of preparing the cell patterning material, a cell patterning method using the cell patterning material, and a biosensor including patterned cells obtained by using the cell patterning method are provided. According to the present disclosure, cells may be conveniently and efficiently patterned and the time for applying external stimulation for patterning may be controlled. In addition, the patterned cells may have an excellent proliferation rate and excellent differentiation efficiency, and may be re-patterned in a different direction, and High-throughput screening using the patterned cells is possible.

Abstract: An exosome active formulation for inhibiting endothelial cell migration, and a preparation method and use thereof include the following steps: isolating primary umbilical vein endothelial cells and performing cell culture and passage; adding anisodamine to a culture medium of the subcultured endothelial cells to pretreat the endothelial cells, and then replacing the culture medium with a new endothelial cell culture medium and adding TNF-? to continue the culture of the endothelial cells; extracting exosomes from the TNF-? containing endothelial cell culture medium obtained after the endothelial cells are cultivated; and identifying the exosomes. The exosome active formulation for inhibiting endothelial cell migration prepared by the preparation method of this disclosure and its use in the antitumor drugs.

Abstract: An exosome active formulation for promoting endothelial cell angiogenesis, and a preparation method and use thereof include the following steps: isolating primary umbilical vein endothelial cells and performing cell culture and passage; adding anisodamine to a culture medium of the subcultured endothelial cells to treat the endothelial cells, and then replacing the culture medium with a new endothelial cell culture medium to continue the culture of the endothelial cells; extracting exosomes from the endothelial cell culture medium obtained after the endothelial cells are cultivated; and identifying the exosomes. The exosome active formulation for promoting endothelial cell angiogenesis prepared by the preparation method and its use in the manufacture of a medicament for treating microvascular injury, microcirculation dysfunction and cardio-cerebral infarction.

Abstract: Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.

Abstract: The present invention relates to membranes comprising at least two types of porosity: —a porosity of small size but of high density, allowing for the support and nutrition of culture cells in such a way as to obtain a reconstructed tissue model, and—a porosity of large size but of low density, allowing for the circulation of some cell types and the passage of cytoplasmic extensions from one compartment to another.

Abstract: The invention relates to methods, compositions and kits for determining the cleanness of a surface. Described herein is a kit for determining the cleanness of a surface comprising an enzymatic solution comprising catalase; and a developer solution comprising hydrogen peroxide. Described also is a method for determining the cleanness of a surface comprising: applying on a zone of a surface to be cleaned an enzymatic solution comprising catalase and letting it dry; after cleaning said surface, applying on said zone a developer solution comprising hydrogen peroxide; and detecting a catalytic reaction between remaining catalase and hydrogen peroxide, wherein presence of a catalytic reaction is indicative of a surface not properly cleaned. Also provided are specific enzymatic solutions and developer solutions for the kits and methods.

Abstract: The present invention relates to a process of remediating wastewaters, preferably agricultural wastewaters resulting from animal production or contained animal feeding operation sites. The water is treated to promote assimilation of nutrients into algal biomass, which can be harvested and sold, and the resultant wastewater is then purified. According to the invention, short wavelength UV radiation (less than 280 nm wavelength) is used to pretreat wastewater, with the dose determined by absorbance of the water, not by bacterial load. Pretreated water exhibits changes in chromophoric dissolved organic matter that allows for improved and increased algae production by as much as 88%.

Abstract: Therapeutic compositions are described for the treatment of a variety of conditions including heart, eye, lungs, organs, joints, dermal, nerve, and the like. A therapeutic composition may be a fluid comprising amniotic fluid or micronized amniotic particles. A therapeutic composite may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. In another embodiment, the therapeutic composite is a mixture of micronized amniotic membrane particles combined with an amniotic rich stem cell fluid. An amniotic rich or concentrated stem cell fluid comprises at least 0.5×106 amniotic stem cells per milliliter of fluid or composition. A therapeutic composite may be used to treat any number of conditions through topical application, surgical introduction, and/or injection.

Abstract: There is provided a process for growing a phototrophic biomass in a reaction zone, wherein the reaction zone includes a reaction mixture that is operative for effecting photosynthesis upon exposure to photosynthetically active light radiation, wherein the reaction mixture includes phototrophic biomass that is operative for growth within the reaction zone. The process includes supplying at least a fraction of gaseous exhaust material, being discharged from an industrial process, to the reaction zone, exposing the reaction mixture to photosynthetically active light radiation and effecting growth of the phototrophic biomass in the reaction zone, wherein the effected growth includes growth effected by photosynthesis, and modulating distribution of a molar rate of supply of carbon dioxide, being exhausted from the reaction zone, as between a smokestack and at least another point of discharge.

Abstract: The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver.

Abstract: Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane.

Abstract: A process for preparing an algal powder containing a reduced content of proteins, a bioplastic composition formed from such a powder, a process for manufacturing a plastic product obtained from such an algal powder and also the plastic product obtained in this way. Process for preparing an algal powder, especially intended for the manufacture of a plastic product, including the successive steps of: culturing and/or harvesting an algal biomass; reducing by at least 10% the intrinsic amount of proteins of the algae, by weight relative to the weight of proteins of the harvested biomass; drying; and reducing to give powder or granules.

Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.

Abstract: Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of amnion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.

Abstract: Described herein are tissue grafts derived from the placenta that possess good adhesion to biological tissues and are useful in would healing applications. In one aspect, the tissue graft includes (1) two or more layers of amnion, wherein at least one layer of amnion is cross-linked, (2) two or more layers of chorion, wherein at least one layer of amnion is cross-linked, or (3) one or more layers of amnion and chorion, wherein at least one layer of amnion and/or chorion is cross-linked. In another aspect, the grafts are composed of amnion and chorion cross-linked with one another. In a further aspect, the grafts have one or more layers sandwiched between the amnion and chorion membranes. The amnion and/or the chorion are treated with a cross-linking agent prior to the formation of the graft. The presence of the cross-linking agent present on the graft also enhances adhesion to the biological tissue of interest. Also described herein are methods for making and using the tissue grafts.